Αρχική World News FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma World News FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Από Ogkologos - 28 Ιανουαρίου, 2026 554 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma 29 Απριλίου, 2021 Her Mother Died of Breast Cancer When She Was Five. 16... 25 Ιουνίου, 2019 Treating the Whole Person: How Cancer Centers Are Addressing Social Needs 18 Ιουλίου, 2024 4-Year-Old Secretly Told Teacher His Dad Was Sick, And She Donated... 4 Σεπτεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast...